Page 28 - Bio Developments News Today

Adcendo has expanded its partnership with fellow biotech company Duality Biologics, in an effort to "broaden and expand" the collaboration.

Government-owned company Genomics England has partnered with bioinformatics firm Seqera Labs to advance cancer care in the NHS.

AstraZeneca has announced positive high-level data from its DUO-E phase 3 trial for patients with endometrial cancer.

Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.

Danish early-stage biotech company InProTher has raised €6M seed funding from private investors to advance its lead drug candidate IPT001.

Neurimmune has announced that primary results of its phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC), and published in The New England Journal of Medicine.

Locate Bio, a UK-based orthobiologics company, has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft.

Moderna has reported interim phase 1/2 data for mRNA-3927, its mRNA therapy targeted at propionic acidemia (PA).

US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

Lumen Bioscience has announced that the US Food and Drug Administration (FDA) has granted fast track designation for LMN-201, its biologic drug to treat and prevent C. difficile infection (CDI).